 Connection
Margaret Macy to Antineoplastic Agents
This is a "connection" page, showing publications Margaret Macy has written about Antineoplastic Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.555 |
|
|
|
-
Pearson AD, Chi S, Laetscht TW, Marshall L, Raetz E, George RE, Chesler L, Karres D, Scobie N, Knoderer H, Weigel B, Teachey D, Sonke GS, Seibel N, Pappo A, Nysom K, Muscal J, Molenaar J, McDonough J, Macy ME, Ludwinski D, Lin C, Ligas F, Lesa G, Knox L, Kirschbaum M, Kieran M, Kholmanskikh O, Jacobson A, Heenen D, Hawkins DS, Glade Bender J, Fox E, Demolis P, de Rojas T, Cox MC, Chauvin B, Blanc P, Vassal G. Paediatric strategy forum for medicinal product development of cyclin-dependent kinase inhibitors in children and adolescents ACCELERATE in collaboration with the European Medicines Agency With participation of the Food and Drug Administration. Eur J Cancer. 2025 Aug 26; 226:115629.
Score: 0.107
-
DuBois SG, Moreno L, Anderson J, Asgharzadeh S, Bagatell R, Beck-Popovic M, Belle J, Berlanga P, Bird NJ, Chesler L, Durbin A, Eggert A, Eilers M, Federico SM, Fischer M, Gatz SA, George RE, George S, Goldsmith KC, Gray J, Heczey A, Irwin MS, Knox L, Lode HN, Ludwinski D, Macy ME, Majzner RG, Maris JM, Modak S, Molenaar JJ, Morgenstern DA, Mossé YP, Owens C, Reynolds CP, Rossig C, Schleiermacher G, Scott L, Sondel PM, Speleman F, van Noesel M, Westermann F, Wienke J, Wolpaw AJ, Park JR, Pearson ADJ. Accelerating Drug Development for Neuroblastoma: Consensus Statement From the Third Neuroblastoma Drug Development Strategy Forum. Pediatr Blood Cancer. 2025 Sep; 72(9):e31831.
Score: 0.106
-
Laetsch TW, DuBois SG, Bender JG, Macy ME, Moreno L. Opportunities and Challenges in Drug Development for Pediatric Cancers. Cancer Discov. 2021 03; 11(3):545-559.
Score: 0.077
-
Rossoff J, Huynh V, Rau RE, Macy ME, Sulis ML, Schultz KR, Burke MJ, Athale U, O'Brien MM, Gregory JJ, van der Sluis IM, Keller FG, Zwaan CM, Suttorp M, Hijiya N. Experience with ponatinib in paediatric patients with leukaemia. Br J Haematol. 2020 04; 189(2):363-368.
Score: 0.073
-
Frappaz D, Federico SM, Pearson AD, Gore L, Macy ME, DuBois SG, Aerts I, Iannone R, Geschwindt R, Van Schanke A, Wang R, Geoerger B. Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours. Eur J Cancer. 2016 07; 62:9-17.
Score: 0.056
-
Norris RE, Shusterman S, Gore L, Muscal JA, Macy ME, Fox E, Berkowitz N, Buchbinder A, Bagatell R. Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumors. Pediatr Blood Cancer. 2014 Oct; 61(10):1792-7.
Score: 0.050
-
Bagatell R, Herzog CE, Trippett TM, Grippo JF, Cirrincione-Dall G, Fox E, Macy M, Bish J, Whitcomb P, Aikin A, Wright G, Yurasov S, Balis FM, Gore L. Pharmacokinetically guided phase 1 trial of the IGF-1 receptor antagonist RG1507 in children with recurrent or refractory solid tumors. Clin Cancer Res. 2011 Feb 01; 17(3):611-9.
Score: 0.039
-
Pearson AD, DuBois SG, Macy ME, de Rojas T, Donoghue M, Weiner S, Knoderer H, Bernardi R, Buenger V, Canaud G, Cantley L, Chung J, Fox E, Friend J, Glade-Bender J, Gorbatchevsky I, Gore L, Gupta A, Hawkins DS, Juric D, Lang LA, Leach D, Liaw D, Lesa G, Ligas F, Lindberg G, Lindberg W, Ludwinski D, Marshall L, Mazar A, McDonough J, Nysom K, Ours C, Pappo A, Parsons DW, Rosenfeld A, Scobie N, Smith M, Taylor D, Weigel B, Weinstein A, Karres D, Vassal G. Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3ß inhibitors in children and adolescents with cancer. Eur J Cancer. 2024 Aug; 207:114145.
Score: 0.025
-
Gore L, Trippett TM, Katzenstein HM, Boklan J, Narendran A, Smith A, Macy ME, Rolla K, Narashimhan N, Squillace RM, Turner CD, Haluska FG, Nieder M. A multicenter, first-in-pediatrics, phase 1, pharmacokinetic and pharmacodynamic study of ridaforolimus in patients with refractory solid tumors. Clin Cancer Res. 2013 Jul 01; 19(13):3649-58.
Score: 0.011
-
Cohen KJ, Gibbs IC, Fisher PG, Hayashi RJ, Macy ME, Gore L. A phase I trial of arsenic trioxide chemoradiotherapy for infiltrating astrocytomas of childhood. Neuro Oncol. 2013 Jun; 15(6):783-7.
Score: 0.011
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|